Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335093 | PMC |
| http://dx.doi.org/10.3324/haematol.2022.281481 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Opportunistic bone density assessment using pre-treatment [18F]FDG-PET/CT identifies fracture risk in lymphoma patients undergoing corticosteroid-containing chemotherapy.
Haematologica
January 2025
Clinical Haematology, Austin Health, Heidelberg; Lymphoma Clinical Innovations Group, Olivia Newton John Cancer and Research Institute, Austin Hospital, Heidelberg; Department of Medicine, University of Melbourne, Melbourne; Department of Medical Oncology, Austin Hospital, Heidelberg; School of Public Health and Preventative Medicine, Monash University.
Not available.
View Article and Find Full Text PDFInterplay between circulating von Willebrand factor and neutrophils: implications for inflammation, neutrophil function, and von Willebrand factor clearance.
Haematologica
January 2025
Institute of Experimental Haematology and Transfusion Medicine, University Hospital Bonn, Bonn.
Von Willebrand factor (VWF) plays a critical role in hemostasis, and emerging evidence suggests its involvement in inflammation. Our study aimed to investigate the interaction between circulating plasma VWF and neutrophils (polymorphonuclear cells, PMNs), elucidate the fate of VWF after binding, and explore its impact on neutrophil behavior. Neutrophils were isolated from the whole blood of healthy volunteers, and their interaction with plasma VWF was examined ex vivo.
View Article and Find Full Text PDFMolecular measurable residual disease by immunoglobulin gene rearrangements on circulating tumor DNA predicts outcome in diffuse large B-cell lymphoma.
Haematologica
December 2024
Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome.
In diffuse large B-cell lymphoma (DLBCL) treatment response relies on imaging. We investigated the potential value of molecular measurable residual disease (MRD) on circulating tumor DNA (ctDNA) to predict patient outcomes. We retrospectively evaluated 73 patients.
View Article and Find Full Text PDFA novel prognostic nomogram based on imaging and molecular parameters for newly diagnosed extranodal natural killer/T-cell lymphoma patients.
Haematologica
January 2025
Medical Center of Hematology, Xinqiao Hospital, Army Medical University, Chongqing, 400038, China; State Key Laboratory of Trauma and Chemical Poisoning, Chongqing Key Laboratory of Hematology and Microenvironment, Jinfeng Laboratory, Chongqing, 401329, China; National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
Checkpoint inhibition enhances cell contacts between CD4 T cells and Hodgkin-Reed-Sternberg cells of classic Hodgkin lymphoma.
Haematologica
October 2024
Dr. Senckenberg Institute of Pathology, Goethe University Frankfurt am Main, Theodor-Stern-Kai 7, D-60590 Frankfurt a. Main.
Although checkpoint molecules like CTLA-4 and PD1 have been described several years ago, checkpoint inhibitors such as nivolumab (an anti-PD-1 antibody) have only recently been used to treat classic Hodgkin lymphoma (cHL). Several studies have shown convincing therapeutic effects of nivolumab in cHL. However, the mechanism of action of nivolumab in cHL is not fully understood.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!